151 related articles for article (PubMed ID: 30955398)
21. The prognostic roles of and correlation between
Chang HH; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Hsu WM; Jeng YM; Jou ST
J Clin Pathol; 2020 Mar; 73(3):154-161. PubMed ID: 31542727
[TBL] [Abstract][Full Text] [Related]
22. [Clinicopathologic features of peripheral neuroblastic tumors].
Yang BF; Fu LB; He LJ
Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):305-10. PubMed ID: 24004586
[TBL] [Abstract][Full Text] [Related]
23. High levels of expression and nuclear localization of interleukin-1 beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas.
Nakagawara A; Nakamura Y; Ikeda H; Hiwasa T; Kuida K; Su MS; Zhao H; Cnaan A; Sakiyama S
Cancer Res; 1997 Oct; 57(20):4578-84. PubMed ID: 9377572
[TBL] [Abstract][Full Text] [Related]
24. The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo.
Schulte JH; Pentek F; Hartmann W; Schramm A; Friedrichs N; Øra I; Koster J; Versteeg R; Kirfel J; Buettner R; Eggert A
Int J Cancer; 2009 May; 124(10):2488-94. PubMed ID: 19142969
[TBL] [Abstract][Full Text] [Related]
25. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical detection of ALK protein identifies APC mutated medulloblastoma and differentiates the WNT-activated medulloblastoma from other types of posterior fossa childhood tumors.
Łastowska M; Trubicka J; Karkucińska-Więckowska A; Kaleta M; Tarasińska M; Perek-Polnik M; Sobocińska AA; Dembowska-Bagińska B; Grajkowska W; Matyja E
Brain Tumor Pathol; 2019 Jan; 36(1):1-6. PubMed ID: 30523493
[TBL] [Abstract][Full Text] [Related]
27. The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.
Mus LM; Lambertz I; Claeys S; Kumps C; Van Loocke W; Van Neste C; Umapathy G; Vaapil M; Bartenhagen C; Laureys G; De Wever O; Bexell D; Fischer M; Hallberg B; Schulte J; De Wilde B; Durinck K; Denecker G; De Preter K; Speleman F
Sci Rep; 2020 Jan; 10(1):218. PubMed ID: 31937834
[TBL] [Abstract][Full Text] [Related]
28. High Oct4 expression: implications in the pathogenesis of neuroblastic tumours.
Monferrer E; Burgos-Panadero R; Blanquer-Maceiras M; Cañete A; Navarro S; Noguera R
BMC Cancer; 2019 Jan; 19(1):1. PubMed ID: 30606139
[TBL] [Abstract][Full Text] [Related]
29. HuC/D expression in small round cell tumors and neuroendocrine tumors: a useful tool for distinguishing neuroblastoma from childhood small round cell tumors.
Takemoto J; Kuda M; Kohashi K; Yamada Y; Koga Y; Kinoshita I; Souzaki R; Taguchi T; Oda Y
Hum Pathol; 2019 Mar; 85():162-167. PubMed ID: 30468801
[TBL] [Abstract][Full Text] [Related]
30. The ganglioside G
Balis FM; Busch CM; Desai AV; Hibbitts E; Naranjo A; Bagatell R; Irwin M; Fox E
Pediatr Blood Cancer; 2020 Jan; 67(1):e28031. PubMed ID: 31612589
[TBL] [Abstract][Full Text] [Related]
31. ALK amplification and protein expression predict inferior prognosis in neuroblastomas.
Wang M; Zhou C; Sun Q; Cai R; Li Y; Wang D; Gong L
Exp Mol Pathol; 2013 Oct; 95(2):124-30. PubMed ID: 23797004
[TBL] [Abstract][Full Text] [Related]
32. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases.
Gambini C; Conte M; Bernini G; Angelini P; Pession A; Paolucci P; Donfrancesco A; Veneselli E; Mazzocco K; Tonini GP; Raffaghello L; Dominici C; Morando A; Negri F; Favre A; De Bernardi B; Pistoia V
Virchows Arch; 2003 Jun; 442(6):555-62. PubMed ID: 12709798
[TBL] [Abstract][Full Text] [Related]
33. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.
Regairaz M; Munier F; Sartelet H; Castaing M; Marty V; Renauleaud C; Doux C; Delbé J; Courty J; Fabre M; Ohta S; Vielh P; Michiels S; Valteau-Couanet D; Vassal G
Am J Pathol; 2016 Feb; 186(2):435-45. PubMed ID: 26687816
[TBL] [Abstract][Full Text] [Related]
34. [Correlation between typing of peripheral neuroblastic tumors and prognosis: a clinicopathologic study of 135 cases].
YIN MZ; ZHANG ZD; MA J; SHEN P; CHEN JF; ZHANG HZ
Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):151-5. PubMed ID: 21575383
[TBL] [Abstract][Full Text] [Related]
35. The neuroendocrine and neural profiles of neuroblastomas, ganglioneuroblastomas, and ganglioneuromas.
Molenaar WM; Baker DL; Pleasure D; Lee VM; Trojanowski JQ
Am J Pathol; 1990 Feb; 136(2):375-82. PubMed ID: 1689542
[TBL] [Abstract][Full Text] [Related]
36. Comparison of ultrastructural features among neuroblastic tumors: maturation from neuroblastoma to ganglioneuroma.
Hicks MJ; Mackay B
Ultrastruct Pathol; 1995; 19(4):311-22. PubMed ID: 7571090
[TBL] [Abstract][Full Text] [Related]
37. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Van den Eynden J; Umapathy G; Ashouri A; Cervantes-Madrid D; Szydzik J; Ruuth K; Koster J; Larsson E; Guan J; Palmer RH; Hallberg B
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459281
[TBL] [Abstract][Full Text] [Related]
38. Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas.
Yan B; Kuick CH; Lim M; Venkataraman K; Tennakoon C; Loh E; Lian D; Leong MY; Lakshmanan M; Tergaonkar V; Sung WK; Soh SY; Chang KT
PLoS One; 2014; 9(9):e106575. PubMed ID: 25188507
[TBL] [Abstract][Full Text] [Related]
39. Multiple Immunofluorescence Imaging Analysis Reveals Differential Expression of Disialogangliosides GD3 and GD2 in Neuroblastomas.
Nishimaki H; Nakanishi Y; Yagasaki H; Masuda S
Pediatr Dev Pathol; 2022; 25(2):141-154. PubMed ID: 34674560
[TBL] [Abstract][Full Text] [Related]
40. Tubedown expression correlates with the differentiation status and aggressiveness of neuroblastic tumors.
Martin DT; Gendron RL; Jarzembowski JA; Perry A; Collins MH; Pushpanathan C; Miskiewicz E; Castle VP; Paradis H
Clin Cancer Res; 2007 Mar; 13(5):1480-7. PubMed ID: 17332292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
